Market capitalization | $4.12m |
Enterprise Value | $2.15m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.15 |
P/S ratio (TTM) P/S ratio | 4.12 |
P/B ratio (TTM) P/B ratio | 6.13 |
Revenue growth (TTM) Revenue growth | 978.39% |
Revenue (TTM) Revenue | $1.00m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:
1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:
Mar '25 |
+/-
%
|
||
Revenue | 1 1 |
1,011%
1,011%
|
|
Gross Profit | 0.91 0.91 |
9,000%
9,000%
|
|
EBITDA | -14 -14 |
10%
10%
|
EBIT (Operating Income) EBIT | -14 -14 |
10%
10%
|
Net Profit | -13 -13 |
58%
58%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.
Head office | United States |
CEO | Raghu Rao |
Employees | 13 |
Founded | 2011 |
Website | www.sonnetbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.